Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From Last post Lookie!!
Guidance
Influenza vaccine: ovalbumin content
Data on the ovalbumin content of the influenza vaccines for the 2020 to 2021 flu season.
https://www.gov.uk/government/publications/influenza-vaccine-ovalbumin-content
Group Blank
Therefore we formulate virosomes and liposomes in our lab and surface-label them with ovalbumin (OVA), our protein of interest and a fluorescent dye (Atto647N) for detection by flow cytometry (FACS) and laser scanning microscopy (LSM). ... Furthermore a mouse model of allergic asthmatic airway disease will be used to assess the potential of virosomes and liposomes as novel therapeutic agent for immune-modulation.
https://www.suche.unibe.ch/?eingabe=virosome
We employed virosomes coupled to ovalbumin (OVA) to study their interaction with murine bone marrow-derived dendritic cells (BMDCs) and modulation of downstream T cell responses
https://www.sciencedirect.com/science/article/abs/pii/S1549963417300229?via%3Dihub
https://pubmed.ncbi.nlm.nih.gov/28214610/
Adjuvants and Delivery: Improving on Vaccine Immunogenicity ...
www.ncbi.nlm.nih.gov › pmc › articles
Experiments performed with the model antigen ovalbumin (ova) in vitro showed that ova-loaded, fusion-active virosomes induced a potent ova-specific MHC class I-mediated response. No response was induced by free ova and by ova-loaded, fusion-inactive virosomes.
Dr. Jan Wilschut,[1] of the University of Groningen, The Netherlands,
Author: Elena Armandola
Cited by: 5
Publish Year: 2004
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1140700/
Meet The Electronic Body Part That Can Sniff Out Lung Diseases
University Of Bern!!
Our bodies have their way of identifying signals that we can't consciously detect. One example is a human being's breathprint, which is a chemical biomarker that can be used to diagnose lung complications like COPD, asthma, lung cancer, and even COVID-19.
This newly designed E-Nose has a high level of accuracy and can produce an analysis in just a few minutes. Unlike earlier versions, this new model is reusable, compact, and can be used at room temperature. Individuals with asthma or COPD are particularly susceptible to COVID-19, so the E-Nose has the potential to be a game-changer in order to detect the existence of the virus faster.
https://www.btimesonline.com/articles/132312/20200519/meet-the-electronic-body-part-that-can-sniff-out-lung-diseases.htm
Hmmmm!! What's this Mymetics?
jorge adornetto
Responsable en Mymetics Corporation
Argentina
https://www.linkedin.com/in/jorge-adornetto-981bba120/
Joey Gomez
Cookrem at Mymetics Corporation
Las Vegas, Nevada, United States
https://www.linkedin.com/in/joey-gomez-6b5760161/
marcelo contreras
mmmmmmm en Mymetics Corporation
Estación Central, Santiago Metropolitan, Chile
https://www.linkedin.com/in/marcelo-contreras-1a5675163/
Courtney Kinder
Coordinator at Mymetics Corporation
Lincoln, Nebraska Metropolitan Area
https://www.linkedin.com/in/courtney-kinder-90a1a1133/
Reposting this great news!! :)
Dynamism in medical research
Several organisations and research institutions have already taken advantage of the opportunity and launched various projects. In the medical world, the Vaud-based biotech company Mymetics is currently developing a unique vaccine in collaboration with the University Hospital of Bern. The team is conducting research to create a prophylactic nasal vaccine. Most of the Covid-19 vaccines currently under development or being deployed in vaccination campaigns are administered by intramuscular injection to induce immune defense responses in the blood. According to the scientific teams, however, there is no or only very limited protection in the nasal area, although this is the main point of entry and replication site for the virus. This vaccine will induce immune protection not only in the blood but will also elicit immune defense protection in the nasal and pulmonary mucous membranes and therefore aims to prevent transmission of the virus and infection at a very early stage before it spreads to other organs. Other teams are aiming to improve vaccine efficacy and long-term immunity.
https://www.innosuisse.ch/inno/en/home/funding-business-information/covid-19-innovation/innovation-projects.html
The life-sciences incubator in Geneva
https://www.fondationeclosion.ch/#portfolio
New Blackeye of Biopole
June 2021, Lausanne, Switzerland
Superlab Suisse Lausanne SA
Building Serine
Route De La Corniche 6,
1066 Epalinges, Lausanne
Switzerland
Superlab Suisse AG
Tödistrasse 1
8002, Zürich
Switzerland
https://superlabsuisse.com/
https://superlabsuisse.com/team/dr-thilo-schroder/
https://superlabsuisse.com/team/dr-konstantinos-efthymiopoulo/
https://superlabsuisse.com/team/zhang-xi/
THOMAS WIDMER APPOINTED AS INNOSUISSE SPECIAL COACH IN LICENSING, ALLIANCES AND M&A
24 FEBRUARY 2020
Thomas Widmer, Counsel at LALIVE, has been appointed as Special Coach in licensing, alliances and M&A by Innosuisse, the Swiss Innovation Agency. Innosuisse promotes science-based innovation in the interests of industry and society in Switzerland and offers sponsorship to selected start-ups and scale-ups. Thomas will be providing Innosuisse sponsored companies with legal advice on contractual and intellectual property issues arising in the context of licensing, alliances and mergers & acquisitions.
Thomas Widmer has extensive experience in intellectual property and is highly recommended in this field by his peers and clients in the main legal directories.
For more information about our Intellectual Property practice, please see here.
LATEST NEWS
SWITZERLAND DESIGNATES MATTHIAS SCHERER TO THE ICSID PANEL OF ARBITRATORS
5 FEBRUARY 2021
LALIVE LITIGATION PARTNERS’ APPOINTMENTS AT THE IBA
27 JANUARY 2021
WHO’S WHO LEGAL RECOGNISES 19 LALIVE PRACTITIONERS IN ITS ARBITRATION GUIDE 2021
18 DECEMBER 2020
For all media and marketing enquiries, please contact the marketing team
+41 58 105 2000
https://www.lalive.law/news/thomas-widmer-appointed-as-innosuisse-special-coach-in-licensing-alliances-and-ma/
Innosuisse & Basel-Stadt present new funding schemes stimulating science-based innovation mitigating the impact of Covid-19
10 February 2021
Share:
Altorfer, Michael / Hess, Samuel / Kohlermann, Felix / Staehelin, Matthias / Lecaudé, Stéphanie / Hausammann, René, Innosuisse & Basel-Stadt present new funding schemes stimulating science-based innovation mitigating the impact of Covid-19, Webinar, February 3, 2021
Agenda:
Impact of Covid pandemic on Swiss biotech companies
Michael Altorfer, CEO, Swiss Biotech Association
Basel-Stadt subordinated loan guarantee program:
Purpose, objectives, and design
Samuel Hess, Department of Economic, Social and Environmental Affairs, Basel-Stadt
Target companies and application process
Felix Kohlermann, Department of Economic, Social and Environmental Affairs, Basel-Stadt
Legal aspects (loan & warrant agreements)
Matthias Staehelin, President BioValley, VISCHER Anwälte
Federal innovation impulse program “Swiss Innovation Power”
Stéphanie Lecaudé, Scientific Officer Life Sciences, Innosuisse
Value of Basel-Stadt and Innosuisse innovation programs from the perspective of other regions
René Hausammann, President, Swissparks.ch
Aufzeichnung
Author: Matthias Staehelin
Presentation (0.97 MB) https://www.vischer.com/fileadmin/uploads/vischer/Documents/Publications_Presentations/MST_Presentations_3_Feb_2021_Innovation_Innosuisse__BS.pdf
https://www.vischer.com/en/knowledge/publications-presentations/innosuisse-basel-stadt-present-new-funding-schemes-stimulating-science-based-innovation-mitigating-the-impact-of-covid-19-38933/
Finally said it!! We all knew this!! :) Innosuisse
Swiss Innovation Agency Government Administration Bern
Website http://www.innosuisse.ch Industry Government Administration Company size 51-200 employees 302
Includes members with current employer listed as Innosuisse, including part-time roles. Type Government Agency Founded 2018 Specialties Innovations funding, science-based innovation, innovation projects, start-up training courses, start-up coaching, networking, and knowledge and technology transfer.
Professor Geert Leroux-Roels: "I would dare to use AstraZeneca in the over-55s"
https://www.nieuwsblad.be/cnt/dmf20210302_93461920
Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects
Investigators
Principal Investigator: Geert Leroux-Roels, Prof. Dr. CEVAC, University of Ghent, Belgium
Study Chair: Sylvain Fleury, PhD Mymetics Corporation
https://clinicaltrials.gov/ct2/show/NCT01084343
Do not for get Prof. Geert LEROUX-ROELS!! :)
Yep! Going to take a universal Covid Vaccine!!
Baylor College of Medicine / Texas Children's
University of Bern
Helmholtz HZI
Merck
Mymetics
Maybe more!!!
That's the team! Get it Done!!!!
You getting old, Your still a young buck compared to me!! :)
I might have know, But forgot!! Old Fart me!! Nice Find Friend!!
Yes, Company always trying to hide info from us investors!! They should know by now it will not work. :)
LET'S GET IT DONE KEMPER'S
Understanding COVID-19 Vaccines and Their Development
www.researchgate.net/publication/343399943...
demonstrated that pDNA can enter animal host cells and can. ... Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, Jones K, Zhan B, ... During the current COVID-19 crisis, it appeared that ...
Once pDNA is introduced into host cells, it can synthe-size viral antigens that are recognized as non-self, promptingthe host immune system to generate an antibody and the CD81cytotoxic T-cell response. This method of vaccine development shares advantages similar to those previously listed for mRNA vaccines (Table II). Additionally, nucleic acids are simpler struc-tures that obviate the potential issues with protein folding, which can hinder recombinant protein-based vaccines.
pDNA can replicate autonomously using host machinery
https://www.researchgate.net/publication/343399943_Understanding_COVID-19_Vaccines_and_Their_Development
Catalent will also acquire Delphi’s proprietary STABY technology, an antibiotic-free selection system for plasmid and protein production in E. coli, which has been validated and licensed on a non-exclusive basis to leading pharmaceutical companies.
Nasal Vaccination, Escherichia coli Enterotoxin, and Bell's ...
www.nejm.org/doi/full/10.1056/NEJMp048006
Perspective from The New England Journal of Medicine — Nasal Vaccination, Escherichia coli Enterotoxin, and Bell's Palsy ... Case 22-2020: A 62-Year-Old Woman ... From the Baylor College of .
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160789400
Table of Contents — December 8, 1995, 270 (49)
www.jbc.org/content/270/49.toc
and Toon Stegmann; J. Biol. Chem ... The Essential Arginine Residue at Position 210 in the a Subunit of the Escherichia coli ATP Synthase Can Be Transferred to ...
Did not know this!! nice find Friend!! ;) Wowser!!
Dr. Jan Wilschut
Member scientific advisory board Merck Sharp & Dohme BV in Haarlem
Other positions
Additional activities:
· Founder and member scientific advisory board “start-up” biotech company “ViciniVax” BV, Groningen
· Founder and consultant “Mymetics” BV, Leiden
· Advisor Dutch Health Council, The Hague
· Member scientific advisory board Merck Sharp & Dohme BV, Haarlem
· President Netherlands Committee for Medical-Biological Research Training (SMBWO)
· Co-ordinator Netherlands Influenza Vaccine Research Centre (NIVAREC)
Last modified: 01 March 2021 1.44 p.m.
https://www.rug.nl/staff/j.c.wilschut/?lang=en
Dr. Thomas Staehelin
His areas of expertise include international briefs, corporate law, mergers & acquisitions, tax law, contract and commercial law as well as banking and stock market and securities law.
https://www.s-ge.com/en/dr-thomas-staehelin
PR: LEM announces new initiatives for operations in Switzerland and in Malaysia
January 22, 2020, 10:00 PM PST
New global headquarters situated in Meyrin, Geneva
Based since 1983 in Plan-les-Ouates, Geneva, the global headquarters will be
relocated to a new campus "The Hive" in Meyrin, Geneva, with an expected
investment of around CHF 10 million. The new custom-built 7,000 sqm building
will offer a modern work environment, better suited for collaboration, with
the majority of the space dedicated to R&D and innovation. The campus is
already home to other corporations such as Hewlett Packard, with excellent
local amenities and easy access to car, train and airport networks. The first
construction activities are scheduled for February 2020, and completion is
expected in Q3 2021. This new Geneva site will be home to about 250 employees,
out of a total of around 1,500 worldwide.
https://www.bloomberg.com/press-releases/2020-01-23/pr-lem-announces-new-initiatives-for-operations-in-switzerland-and-in-malaysia
This is Interesting: Not sure to make of this???
Ian McNutt
Vice President Research and Development Industry at LEM
Switzerland
Vice President Research and Development Industry
Company Name LEM
Dates Employed Dec 2017 – Present
Employment Duration3 yrs 4 mos
Location Geneva Area, Switzerland
LEM is the market leader in current and voltage transducers in many different applications (renewables, traction, drives, smart grid, medical, automotive)
I am leading the Industry R&D team across four sites in Switzerland, Bulgaria, China and France.
Member of the Industry business line Management Team and extended Executive Committee
Responsible for Intellectual Property within LEM
https://www.linkedin.com/in/ian-mcnutt-9801b64/
Before Anergis SA
Christophe Reymond's research while affiliated with Lem Sa Switzerland and other places
https://www.researchgate.net/scientific-contributions/Christophe-Reymond-39861906
Before Anergis SA
Valerie Boand's research while affiliated with Lem Sa Switzerland and other places
https://www.researchgate.net/scientific-contributions/Valerie-Boand-2069317333
https://www.linkedin.com/in/val%C3%A9rie-boand-b8b243aa/
Use to work for Anergis SA now with Merck!!!!!
samantha duc
Samantha Duc's research while affiliated with Lem Sa Switzerland and other places
https://www.researchgate.net/scientific-contributions/Samantha-Duc-2073622866
Samantha Duc
Site Project Manager chez Merck Life Science
Vevey, Vaud, Switzerland
Healthcare Business of Merck
Total Duration2 yrs 9 mos
Title Site Project Manager
Full-time
Dates Employed Nov 2019 – Present
Employment Duration1 yr 5 mos
Location Aubonne, Vaud, Suisse
https://www.linkedin.com/in/samantha-duc-4310884a/
DO NOT SEE ANY OTHER ANERGIS SA PEOPLE AFFILIATED WITH LEM SA????
NANOCAPSULES: A NEW APPROACH IN DRUG DELIVERY
https://ijpsr.com/bft-article/nanocapsules-a-new-approach-in-drug-delivery/?view=fulltext
Triple co-culture of human alveolar epithelium, endothelium and macrophages for studying the interaction of nanocarriers with the air-blood barrier
Author links open overlay panelAnaCostaabcCristianede Souza Carvalho-WodarzdVítorSeabraeBrunoSarmentoabe Claus-MichaelLehrdf
a
I3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal
b
INEB – Instituto de Engenharia Biomédica, Universidade do Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal
c
ICBAS – Instituto Ciências Biomédicas Abel Salazar, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
d
HIPS – Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research (HZI), Saarland University, Universitäts campus E8.1, 66123 Saarbrücken, Germany
e
CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal
f
Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany
https://www.sciencedirect.com/science/article/pii/S1742706119302806#!
Phase IV Rebif (interferon beta-1a) Merck KGaA; French Institut National de la Sante et de la Recherche Medicale (INSERM) As of Oct. 16, in the Solidarity study, overall in-hospital morality was 12.9% for the 1,412 patients who received interferon beta-1a and 11% for the 2,050 patients in the control group 10/16/20
Melody Sauerborn
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
Melody Sauerborn Mymetics
recombinant human interferon beta-1a (rhIFNß-1a) and its immunogenicity in wild-type and immune-tolerant transgenic mice.https://link.springer.com/article/10.1007/s11095-011-0451-4
https://www.researchgate.net/publication/51100334_Oxidized_and_Aggregated_Recombinant_Human_Interferon_Beta_is_Immunogenic_in_Human_Interferon_Beta_Transgenic_Mice
Finally, Merck KGaA has donated a supply of its interferon beta-1a product Rebif – approved for multiple sclerosis - to France’s INSERM research organisation following a request for use in a COVID-19 clinical trial.
http://www.pmlive.com/pharma_news/trump_calls_on_fda_to_cut_red_tape_as_coronavirus_drug_trials_gather_pace_1329673
Interesting: Oct 6th-9th 2020
Melody Sauerborn, Ph.D., Head, Research and Development, Mymetics BV
https://www.immunogenicitysummit.com/speakers/16
All four commercial rhIFNß products, Betaferon/Betaseron® (Schering, Berlin, Germany and Berlex Laboratories, Montville, New Jersey, USA), Avonex® (Biogen Idec, Cambridge, Massachusetts, USA), Rebif® (Serono, Geneva, Switzerland) and Extavia® (Novartis, Basel, Switzerland), show immunogenicity in patients, but the level of BABs and NABs varies among the products (6). http://europepmc.org/article/PMC/2916121
Yes Sir, All the DD'S here are spot on!! :) Hold it will come!! :)
Hope they bring it my Friend!! Anyone that does not buy here and hold will lose!! IMO!! DD's are right!! :)
It could happen at anytime!! Hope very soon my Friend!! :)
Very Nice!! Let's get it done ASAP!! :)
Phase IV Rebif (interferon beta-1a) Merck KGaA; French Institut National de la Sante et de la Recherche Medicale (INSERM) As of Oct. 16, in the Solidarity study, overall in-hospital morality was 12.9% for the 1,412 patients who received interferon beta-1a and 11% for the 2,050 patients in the control group 10/16/20
Phase II M-5049 EMD Serono, unit of Merck KGaA As of June 25, FDA cleared IND for phase II study assessing effect on preventing or ameliorating hyper-inflammatory response in COVID-19 pneumonia and preventing progression to cytokine storm 6/25/20
https://webcache.googleusercontent.com/search?q=cache:79B7aR9xTIsJ:https://www.bioworld.com/COVID-19-therapeutics-vaccines+&cd=2&hl=en&ct=clnk&gl=us
COVID-19 Vaccines: Global Challenges and Prospects Forum ...
www.sciencedirect.com/science/article/abs/pii/S...
(c) Protein based vaccines, CoV RBD219-N1 Vaccine from Baylor College of Medicine, Texas that is based on a yeast-derived (Pichia pastoris) protein (Hotez and Bottazzi, 2020) and from Anhui Zhifei Longcom Biopharmaceutical Co. Ltd (Dai et al., 2020).
Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.
???????????????
China
https://www.natureindex.com/institution-outputs/china/anhui-zhifei-longcom-biopharmaceutical-co-ltd/5f221b2b1cac4f0cfc494df5
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
https://www.natureindex.com/article/10.1016/j.cell.2020.06.035
May 27, 2020
Merck KGaA, Darmstadt, Germany and Baylor College
of Medicine Announce Collaboration to Advance a
Vaccine Manufacturing Platform to Fight Covid-19
• Company will focus on process development and improvements for
manufacturing Baylor’s Covid-19 vaccine candidates
Darmstadt, Germany, May 27, 2020 – Merck KGaA, Darmstadt, Germany, a leading
science and technology company, and Baylor College of Medicine today announced
today announced an extension of an on ongoing collaboration between Baylor and
the Life Science business of Merck KGaA, Darmstadt, Germany to advance a
manufacturing platform to fight Covid-19, designed to accelerate transition to Phase
1 clinical trials.
https://www.emdgroup.com/press-releases/2020/may/us/Baylor-vaccine-manufacturing-platform-Covid-19-NA.pdf
Baylor College Of Medicine
Pioneered gene chip technology that streamlines diagnosis of genetic and chromosomal diseases.
https://www.bcm.edu/research/baylor-research/achievements
Nice my friend Thanks!! :)
Many billionaires, Major Universities, Scientists, World organizations, It go's on my friend!! :)
Chris was also the Chairman of the Board of Genzyme in Boston. Remember that Dr. Thomas Staehelin was also apart of Genzyme.
Ernesto Bertarelli and Amy Wyss are also collaboration with Business as well. Amy Wyss big part of Anergis SA. Ernesto Bertarelli Stallergenes and merck serono.
From my last post on Prof. Dr Volker Thiel, from University of Bern!!
Our model system using yeast cells shows that it is ideally suited for reconstructing coronaviruses and other viruses
Volker Thiel
https://healthcare-in-europe.com/en/news/coronavirus-clone-produced-in-the-lab.html
He talks about RNA polymerase, and Toon Stegmann from Mymetics was big on that years ago!!
Volker Thiel says: Infectious RNA was then produced in vitro (without yeast cells) using the catalyst T7 RNA polymerase. The resulting RNA was introduced into animal cells, where new, synthetic coronaviruses then multiplied – the clones had been created.
Example:
European Journal of Biochemistry: Vol 269, No 21
febs.onlinelibrary.wiley.com/toc/14321033/2002/...
Oct 17, 2002 · Toon Stegmann; Yannick Poquet ... a fold resembling a double-stranded RNA binding domain scaffold ... protein 2 associate with histone H3/H4 and RNA polymerase II ...
https://febs.onlinelibrary.wiley.com/doi/10.1046/j.1432-1033.2002.03213.x
Looks like Prof. Volker Thiel from University of Bern has a good idea in fighting all the Covid Variants. MYMX in good hands at Bern!! Let's get it done MYMX!!
Prof. Volker Thiel, who heads the Department of Virology at the University of Bern, Switzerland, shared similar concerns. According to him: “Although the vaccines target only the spike gene, they should still mount an immune response that is diverse enough that these new variants should be covered.” He, however, emphasised that more experimental studies were needed.
Most of the COVID-19 vaccines elicit a high amount of antibodies that are able to target different regions of the spike protein and so, some of these antibodies could have the ability to target variants of the novel coronavirus.
At the same time, there research shows that the antibodies generated in the body against the virus are less effective in neutralising the 501Y.V2 variant. This is primarily due to the mutations in the spike protein in the new variant. Certain mutations render the new variant the ability to escape an antibody attack. However, as pointed out by Prof. Thiel, aside from antibodies, there are other elements in the immune system which can facilitate the fight against the mutant variants.
https://www.newsclick.in/COVID-19-Vaccines-Counter-Virus-Variants-Research-Mixed-Results
Our model system using yeast cells shows that it is ideally suited for reconstructing coronaviruses and other viruses
Volker Thiel
https://healthcare-in-europe.com/en/news/coronavirus-clone-produced-in-the-lab.html
Scientific abstract sessions - Journal of Allergy and ...
www.jacionline.org/article/S0091-6749(03)70194-8/...
COVID-19; CURED; Drug Allergy; ... Davos, SWITZERLAND, 3 Pharmacology, University of Bern, Bern, ... 1120 Mometasone Furoate Nasal Spray (MFNS) 100 mcg qd Had a Low ..
https://www.jacionline.org/article/S0091-6749(03)70194-8/fulltext